Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab in Active Psoriatic Arthritis (FUTURE 5)
NCT02404350Phase 3Completed
- Sponsor
- Novartis
- Start
- Aug 2015
- Primary completion
- Aug 2017
- Modality
- Monoclonal Antibodies
- Countries
- 28
01
Overview
A Phase 3 trial of secukinumab in psoriatic arthritis (PsA), sponsored by Novartis. Started Aug 2015; status: completed.
02
Drugs
secukinumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT02404350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02404350.